Land: Canada
Språk: engelsk
Kilde: Health Canada
GANIRELIX (GANIRELIX ACETATE)
ORGANON CANADA INC.
H01CC01
GANIRELIX
250MCG
SOLUTION
GANIRELIX (GANIRELIX ACETATE) 250MCG
SUBCUTANEOUS
0.5ML SYR
Prescription
GONADOTROPIN-RELEASING HORMONE ANTAGONISTS
Active ingredient group (AIG) number: 0146941001; AHFS:
APPROVED
2002-05-01
_ORGALUTRAN® (Ganirelix Acetate Injection) _ _Page 1 of 26 _ [Organon] Confidential PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION ORGALUTRAN ® (Ganirelix Injection) 250 mcg /0.5 mL ganirelix (as ganirelix acetate) Subcutaneous use Gonadotropin-releasing hormone (GnRH) antagonist Organon Canada Inc. 16766 route Transcanadienne Kirkland QC Canada H9H 4M7 www.organon.ca Date of Initial Authorization: August 23, 2002 Date of Revision: January 10, 2024 Submission Control Number: 276208 _ _ _ _ _ _ _ORGALUTRAN® (Ganirelix Injection) _ _ _ _Page 2 of 26_ [Organon] Confidential RECENT MAJOR LABEL CHANGES CONTRAINDICATION Jan 2024 WARNINGS AND PRECAUTIONS Jan 2024 TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics .................................................................................................................... 4 1.2 Geriatrics .................................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................. 4 4 DOSAGE AND ADMINISTRATION ................................................................................. 4 4.1 Dosing Considerations ................................................................................................ 4 4.2 Recommended Dose and Dosage Adjustment ........................................................... 4 4.4 Administration ............................................................................................................ 4 4.5 Missed Dose ............................................................................................. Les hele dokumentet